Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SERA
SERA logo

SERA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Sera Prognostics Inc (SERA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.880
1 Day change
-2.08%
52 Week Range
4.090
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Sera Prognostics Inc (SERA) is not a strong buy for a beginner, long-term investor at this time. The lack of positive trading signals, weak financial performance, insider selling, and absence of significant catalysts suggest holding off on investment until more favorable conditions arise.

Technical Analysis

The MACD histogram is slightly positive at 0.012 and contracting, indicating weak momentum. RSI is neutral at 42.84, and moving averages are converging, showing no clear trend. Key support is at 1.978, and resistance is at 2.314. The stock is trading near its pivot level of 2.146, suggesting limited upside potential in the short term.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
8
Buy
3

Positive Catalysts

  • NULL identified. No recent news or significant positive developments.

Neutral/Negative Catalysts

  • Insider selling has increased significantly by 2019.12% over the last month, indicating potential lack of confidence in the stock. Financial performance in 2025/Q4 showed declining revenue (-58.33% YoY), net income (-8.14% YoY), and EPS (-36.00% YoY). No recent congress trading data or influential figure activity.

Financial Performance

In 2025/Q4, revenue dropped to $10,000 (-58.33% YoY), net income fell to -$7,881,000 (-8.14% YoY), and EPS declined to -0.16 (-36.00% YoY). Gross margin improved significantly but remains negative at -320%. Overall, the financials indicate poor growth trends.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes provided. Wall Street sentiment is unclear, but insider selling suggests a negative outlook.

Wall Street analysts forecast SERA stock price to rise
3 Analyst Rating
Wall Street analysts forecast SERA stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.920
sliders
Low
5
Averages
5
High
5
Current: 1.920
sliders
Low
5
Averages
5
High
5
Jefferies
initiated
$5
AI Analysis
2025-12-14
Reason
Jefferies
Price Target
$5
AI Analysis
2025-12-14
initiated
Reason
Jefferies initiated coverage of Sera Prognostics with a Buy rating and $5 price target. Sera is a women's health diagnostics company developing predictive biomarker testing for pregnancy complications, the analyst tells investors in a research note. The firm says the company's flagship product PreTRM offers a simple blood test for predicting individualized risk for spontaneous preterm birth in asymptomatic pregnancies. Jefferies cites PreTRM's first to market clinical validation, "attractive" $1.6B addressable market in the U.S. and its early traction with Elevance partner and Medicaid pilot programs for the Buy rating.

People Also Watch